The estimated Net Worth of Ltd Juvenescence is at least $182 Milhão dollars as of 13 August 2019. Ltd Juvenescence owns over 19,000 units of AgeX Therapeutics Inc stock worth over $182,250,900 and over the last 5 years Ltd sold AGE stock worth over $0.
Ltd has made over 1 trades of the AgeX Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Ltd bought 19,000 units of AGE stock worth $210,900 on 13 August 2019.
The largest trade Ltd's ever made was buying 19,000 units of AgeX Therapeutics Inc stock on 13 August 2019 worth over $210,900. On average, Ltd trades about 1,000 units every 0 days since 2019. As of 13 August 2019 Ltd still owns at least 16,419,000 units of AgeX Therapeutics Inc stock.
You can see the complete history of Ltd Juvenescence stock trades at the bottom of the page.
Ltd's mailing address filed with the SEC is 1ST FLOOR, VIKING HOUSE, ST PAULS SQUARE, RAMSEY, Y8, IM8 1GB.
Over the last 6 years, insiders at AgeX Therapeutics Inc have traded over $0 worth of AgeX Therapeutics Inc stock and bought 23,000 units worth $15,440 . The most active insiders traders include Gregory Bailey, Michael D West, eJudith Segall. On average, AgeX Therapeutics Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,024. The most recent stock trade was executed by Michael D West on 11 March 2023, trading 3,125 units of AGE stock currently worth $34,688.
agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic candidates in development include agex-bat1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as type ii adult-onset diabetes; and agex-vasc1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. its lead drug-based therapeutic candidate in discovery is agex-itr1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. in addition, the company markets human embryonic stem cells; and genecards database suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. agex therapeutics, inc. ha
AgeX Therapeutics Inc executives and other stock owners filed with the SEC include: